Roche Korea picks 4 Korean biotech firms for K-Swiss BioPass program

FierceBiotechADA: Boehringer execs claim survodutide tolerability 'consistent' with class despite phase 3 update

FierceBiotechRoche bets $700M upfront on Nurix’s late-phase BTK degrader to tee up Lilly showdown

BioPharma DiveInnovation alone is no longer enough in biopharma

BioPharma DivePrecision under pressure: Logistic solutions for nuclear medicine scalability

Roche MediaRoche Korea picks 4 Korean biotech firms for K-Swiss BioPass program - koreabiomed.com

FierceBiotechCould engaging the immune system improve AML outcomes?

FierceBiotechWhy AI is changing clinical development

FierceBiotechManaging complexity across biopharma modalities

eLifeCharacterization and modulation of human insulin degrading enzyme conformational dynamics to control enzyme activity

eLifeA macroevolution-inspired approach to reveal novel antibiotic resistance mechanisms

eLifeA comprehensive mechanosensory connectome reveals a somatotopically organized neural circuit architecture controlling stimulus-aimed grooming of the <i>Drosophila</i> head

NINGBO YONGXIN OPTICS CO., LTD.World Microscope Objectives - Market Analysis, Forecast, Size, Trends and Insights - IndexBox